Advertisement

International Journal of Hematology

, Volume 80, Issue 2, pp 164–167 | Cite as

Acute Respiratory Distress Syndrome during the Third Infusion of Rituximab in a Patient with Follicular Lymphoma

  • Bungo Saito
  • Tsuyoshi Nakamaki
  • Daisuke Adachi
  • Junko Suzuki
  • Shigeru Tomoyasu
Case Report

Abstract

We present the case of a 66-year-old man with follicular lymphoma who developed acute respiratory distress syndrome (ARDS) during a third infusion of rituximab. High fever, tachypnea, and progressive hypoxemia accompanied by massive bilateral pleural effusions appeared suddenly approximately 3 hours after the third infusion was started, although the 2 prior infusions of rituximab had produced only mild adverse effects. The patient was treated successfully with high-dose methylprednisolone and 3 days of mechanical ventilatory support. No evidence was obtained to indicate that the ARDS had been caused by either cytokine release or tumor lysis, and serum human antichimeric antibody was not detected.Although the cause of ARDS was not confirmed, our experience in this case suggested that an anaphylactic reaction induced by repeated infusion of rituximab was involved in the onset of pulmonary disease. Although ARDS is rarely seen with rituximab infusion, careful management is required for safe administration of the newly developed rituximab therapy. This management includes monitoring biological reactions not only during the initial infusion but also during subsequent infusions of the antibody.

Key words

Rituximab Follicular lymphoma Infusion reaction ARDS 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Reff ME, Carner K, Chambers KS, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood. 1994;83:435–445.PubMedGoogle Scholar
  2. 2.
    Shan D, Ledbetter JA, Press OW. Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies. Blood. 1998;91:1644–1652.PubMedGoogle Scholar
  3. 3.
    Coiffier B, Haioun C, Ketterer N, et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood. 1998;92:1927–1932.PubMedGoogle Scholar
  4. 4.
    Czuczman MS, Grillo-Lopez AJ, White CA, et al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol. 1999;17:268–276.CrossRefPubMedGoogle Scholar
  5. 5.
    Feuring-Buske M, Kneba M, Unterhalt M, et al. IDEC-C2B8 (rituximab) anti-CD20 antibody treatment in relapsed advanced-stage follicular lymphomas: results of a phase-II study of the German Low-Grade Lymphoma Study Group. Ann Hematol. 2000;79:493–500.CrossRefPubMedGoogle Scholar
  6. 6.
    Grillo-Lopez AJ. Monoclonal antibody therapy for B-cell lymphoma. Int J Hematol. 2002;76:385–393.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Tobinai K. Monoclonal antibody therapy for B-cell lymphoma: clinical trials of an anti-CD20 monoclonal antibody for B-cell lymphoma in Japan. Int J Hematol. 2002;76:411–419.CrossRefPubMedGoogle Scholar
  8. 8.
    Byrd JC,Waselenko JK, Maneatis TJ, et al. Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: association with increased infusion-related side effects and rapid blood tumor clearance. J Clin Oncol. 1999;17:791–795.CrossRefPubMedGoogle Scholar
  9. 9.
    Winkler U, Jensen M, Manzke O, Schulz H, Diehl V, Engert A. Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8). Blood. 1999;94:2217–2224.PubMedGoogle Scholar
  10. 10.
    van der Kolk LE, Grillo-Lopez AJ,Baars JW, Hack CE, van Oers MH. Complement activation plays a key role in the side-effects of rituximab treatment. Br J Haematol. 2001;115:807–811.CrossRefPubMedGoogle Scholar
  11. 11.
    Kunzmann V, Ruediger T, Hallek M, Mueller-Hermelink HK,Wilhelm M. Tumor cell agglutination and not solely cytokine release as mechanism of adverse reactions during anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) treatment. Blood. 2001;98:1991–1992.CrossRefPubMedGoogle Scholar
  12. 12.
    Yang H, Rosove MH, Figlin RA. Tumor lysis syndrome occurring after the administration of rituximab in lymphoproliferative disorders: high-grade non-Hodgkin’s lymphoma and chronic lymphocytic leukemia. Am J Hematol. 1999;62:247–250.CrossRefPubMedGoogle Scholar
  13. 13.
    Maloney DG, Grillo-Lopez AJ,White CA, et al. IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin’s lymphoma. Blood. 1997;90:2188–2195.PubMedGoogle Scholar
  14. 14.
    Vose JM, Link BK, Grossbard ML, et al. Phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin’s lymphoma. J Clin Oncol. 2001;19:389–397.CrossRefPubMedGoogle Scholar
  15. 15.
    Igarashi T, Kobayashi Y, Ogura M, et al. Factors affecting toxicity, response and progression-free survival in relapsed patients with indolent B-cell lymphoma and mantle cell lymphoma treated with rituximab: a Japanese phase II study. Ann Oncol. 2002;13:928–943.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Maeda T, Yamada Y, Tawara M, et al. Successful treatment with a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) for a patient with relapsed mantle cell lymphoma who developed a human anti-chimeric antibody. Int J Hematol. 2001;74:70–75.CrossRefPubMedGoogle Scholar
  17. 17.
    Baudouin V, Crusiaux A, Haddad E, et al. Anaphylactic shock caused by immunoglobulin E sensitization after retreatment with the chimeric anti-interleukin-2 receptor monoclonal antibody basiliximab. Transplantation. 2003;76:459–463.CrossRefPubMedGoogle Scholar
  18. 18.
    Savage DG, Cohen NS, Hesdorffer CS, et al. Combined fludarabine and rituximab for low grade lymphoma and chronic lymphocytic leukemia. Leuk Lymphoma. 2003;44:477–481.CrossRefPubMedGoogle Scholar

Copyright information

© The Japanese Society of Hematology 2004

Authors and Affiliations

  • Bungo Saito
    • 1
  • Tsuyoshi Nakamaki
    • 1
  • Daisuke Adachi
    • 1
  • Junko Suzuki
    • 1
  • Shigeru Tomoyasu
    • 1
  1. 1.Department of HematologyShowa University School of MedicineTokyoJapan

Personalised recommendations